Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors
Crossref DOI link: https://doi.org/10.1007/s00280-017-3482-7
Published Online: 2017-11-21
Published Print: 2018-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lee, Lingaku
Ito, Tetsuhide
Igarashi, Hisato
Miki, Masami
Fujimori, Nao
Kawabe, Ken
Jensen, Robert T.
Ogawa, Yoshihiro
License valid from 2017-11-21